

# The 2023 Monitoring Program\*

The following substances are placed on the 2023 Monitoring Program:

## 1. Anabolic Agents:

**In** and **Out-of-Competition**: Ecdysterone

## 2. Peptides Hormones, Growth Factors, Related Substances, and Mimetics:

**In** and **Out-of-Competition**: Gonadotrophin-releasing hormone (GnRH) analogs in females under 18 years only.

## 3. Beta-2 Agonists:

**In** and **Out-of-Competition**: Salmeterol and vilanterol below the *Minimum Reporting Level*.

## 4. Hypoxen (polyhydroxyphenylene thiosulfonate sodium):

**In** and **Out-of-Competition**

## 5. Stimulants:

**In-Competition only**: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.

## 6. Narcotics:

**In-Competition only**: Codeine, dermorphin (and its analogs), hydrocodone and tramadol.

\*The World Anti-Doping Code (Article 4.5) states: "WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect potential patterns of misuse in sport."